risperidone Indications/Contra | FAERs | Orange Book | BioActivity |

Stem definitionDrug idCAS RN
antipsychotics, risperidone derivatives 2389 106266-06-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • risperidone
  • ripedon
  • rispadal
  • risperdal
  • risperidal
  • R 64,766
A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
  • Molecular weight: 410.49
  • Formula: C23H27FN4O2
  • CLOGP: 2.71
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 0
  • TPSA: 61.94
  • ALOGS: -3.38
  • ROTB: 4

Drug dosage:

DoseUnitRoute
5 mg O
2.70 mg P

Approvals:

DateAgencyCompanyOrphan
Dec. 29, 1993 FDA JANSSEN PHARMS

FDA Adverse Event Reporting System

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Extrapyramidal disorder 4345.57 35.25 985 24203 4321 4609483
Neuroleptic malignant syndrome 4272.64 35.25 986 24202 4761 4609043
Somnolence 2914.41 35.25 1165 24023 42495 4571309
Suicide attempt 2753.10 35.25 921 24267 19921 4593883
Intentional overdose 2525.85 35.25 873 24315 20893 4592911
Drug interaction 2467.25 35.25 1162 24026 63346 4550458
Weight increased 2316.61 35.25 941 24247 35640 4578164
Psychotic disorder 2180.40 35.25 660 24528 10135 4603669
Treatment noncompliance 2177.41 35.25 676 24512 11351 4602453
Hyperprolactinaemia 2149.37 35.25 418 24770 652 4613152
Sedation 2001.97 35.25 573 24615 7144 4606660
Intentional self-injury 1995.32 35.25 566 24622 6817 4606987
Blood prolactin increased 1960.32 35.25 421 24767 1333 4612471
Dystonia 1849.93 35.25 485 24703 4233 4609571
Completed suicide 1721.61 35.25 798 24390 41647 4572157
Aggression 1705.17 35.25 582 24606 13317 4600487
Parkinsonism 1683.93 35.25 417 24771 2816 4610988
Drug ineffective 1680.82 35.25 1326 23862 184735 4429069
Tardive dyskinesia 1571.89 35.25 396 24792 2893 4610911
Schizophrenia 1554.34 35.25 404 24784 3391 4610413
Dyskinesia 1530.04 35.25 486 24702 8789 4605015
Agitation 1520.15 35.25 620 24568 23580 4590224
Galactorrhoea 1500.85 35.25 330 24858 1200 4612604
Tachycardia 1497.92 35.25 660 24528 30485 4583319
Toxicity to various agents 1492.71 35.25 862 24326 71178 4542626
Catatonia 1481.05 35.25 340 24848 1572 4612232
Akathisia 1479.21 35.25 383 24805 3160 4610644
Gynaecomastia 1441.52 35.25 346 24842 2009 4611795
Off label use 1340.91 35.25 1002 24186 128111 4485693
Overdose 1280.98 35.25 658 24530 42901 4570903
Muscle rigidity 1256.08 35.25 345 24843 3642 4610162
Fall 1204.82 35.25 774 24414 77272 4536532
Condition aggravated 1173.88 35.25 685 24503 57486 4556318
Coma 1168.54 35.25 469 24719 17050 4596754
Rhabdomyolysis 1142.17 35.25 476 24712 19082 4594722
Tremor 1112.64 35.25 564 24624 35695 4578109
Electrocardiogram QT prolonged 1098.49 35.25 432 24756 14863 4598941
Confusional state 1094.38 35.25 616 24572 48218 4565586
Abnormal behaviour 1046.50 35.25 391 24797 11665 4602139
Hypothermia 1008.11 35.25 296 24892 4038 4609766
Hallucination, auditory 975.83 35.25 292 24896 4269 4609535
Blood creatine phosphokinase increased 974.79 35.25 395 24793 14704 4599100
Hyponatraemia 920.14 35.25 439 24749 24291 4589513
Delusion 908.29 35.25 277 24911 4333 4609471
Hypotension 877.88 35.25 602 24586 66798 4547006
Salivary hypersecretion 845.98 35.25 237 24951 2700 4611104
Delirium 827.70 35.25 335 24853 12417 4601387
Suicidal ideation 802.25 35.25 383 24805 21200 4592604
Sopor 778.47 35.25 268 24920 6258 4607546
Restlessness 773.86 35.25 294 24894 9175 4604629
Product use in unapproved indication 753.59 35.25 386 24802 24887 4588917
Pneumonia aspiration 731.11 35.25 284 24904 9422 4604382
Anxiety 721.15 35.25 469 24719 47542 4566262
Priapism 711.50 35.25 181 25007 1375 4612429
Depressed level of consciousness 697.45 35.25 312 24876 14842 4598962
Pleurothotonus 695.57 35.25 143 25045 338 4613466
Hallucination 682.30 35.25 322 24866 17346 4596458
Diabetes mellitus 671.67 35.25 306 24882 15195 4598609
Seizure 658.65 35.25 451 24737 49786 4564018
Insomnia 639.55 35.25 426 24762 44919 4568885
Leukopenia 598.97 35.25 315 24873 21421 4592383
Dysphagia 589.41 35.25 329 24859 25202 4588602
Oculogyric crisis 583.43 35.25 136 25052 678 4613126
Serotonin syndrome 576.78 35.25 220 24968 6932 4606872
Amenorrhoea 565.49 35.25 165 25023 2193 4611611
Altered state of consciousness 560.60 35.25 222 24966 7749 4606055
Dysarthria 554.86 35.25 250 24938 12082 4601722
Urinary retention 508.70 35.25 220 24968 9627 4604177
Hospitalisation 504.54 35.25 320 24868 30985 4582819
Depression 482.11 35.25 366 24822 47367 4566437
Medication error 472.65 35.25 235 24953 14181 4599623
Pulmonary embolism 469.55 35.25 317 24871 34109 4579695
Drug abuse 468.66 35.25 293 24895 27654 4586150
Cognitive disorder 466.74 35.25 211 24977 10270 4603534
Blood prolactin abnormal 466.43 35.25 89 25099 116 4613688
Urinary incontinence 461.80 35.25 189 24999 7191 4606613
Musculoskeletal stiffness 456.38 35.25 251 24937 18651 4595153
Bradycardia 451.49 35.25 265 24923 22304 4591500
Obsessive-compulsive disorder 445.23 35.25 127 25061 1548 4612256
Paranoia 442.55 35.25 161 25027 4428 4609376
Miosis 424.96 35.25 139 25049 2751 4611053
Sinus tachycardia 422.18 35.25 169 25019 6065 4607739
Cogwheel rigidity 420.58 35.25 95 25093 400 4613404
Speech disorder 416.43 35.25 201 24987 11361 4602443
Product use issue 405.93 35.25 257 24931 24779 4589025
Gait disturbance 405.65 35.25 297 24891 36343 4577461
Neutropenia 405.07 35.25 331 24857 47619 4566185
Cardio-respiratory arrest 391.81 35.25 231 24957 19591 4594213
Death 387.82 35.25 640 24548 197523 4416281
Irritability 383.99 35.25 199 24989 13100 4600704
Type 2 diabetes mellitus 379.28 35.25 141 25047 4126 4609678
Mania 377.08 35.25 147 25041 4911 4608893
Sexual dysfunction 375.76 35.25 120 25068 2193 4611611
Loss of consciousness 374.22 35.25 280 24908 35402 4578402
Disorientation 367.11 35.25 189 24999 12270 4601534
Pyrexia 366.24 35.25 452 24736 106692 4507112
Acute kidney injury 360.59 35.25 367 24821 70064 4543740
Sluggishness 358.85 35.25 109 25079 1675 4612129
Exposure during pregnancy 355.28 35.25 263 24925 32708 4581096
Disturbance in attention 351.21 35.25 174 25014 10407 4603397
Hyperthermia 337.10 35.25 122 25066 3302 4610502
Psychomotor hyperactivity 334.53 35.25 128 25060 4061 4609743
Sudden death 334.47 35.25 137 25051 5218 4608586
Cardiometabolic syndrome 333.92 35.25 83 25105 566 4613238
Cardiac arrest 332.58 35.25 256 24932 33751 4580053
Hyperhidrosis 329.86 35.25 242 24946 29675 4584129
Increased appetite 323.30 35.25 111 25077 2562 4611242
Constipation 322.70 35.25 275 24913 41879 4571925
General physical health deterioration 322.29 35.25 235 24953 28543 4585261
Inappropriate antidiuretic hormone secretion 318.23 35.25 126 25062 4388 4609416
Disturbance in social behaviour 317.85 35.25 74 25114 366 4613438
Psychotic symptom 308.74 35.25 74 25114 424 4613380
Incorrect dose administered 304.18 35.25 195 24993 19190 4594614
Social avoidant behaviour 303.92 35.25 89 25099 1197 4612607
Adverse event 302.67 35.25 182 25006 15990 4597814
Obesity 298.84 35.25 106 25082 2702 4611102
Lethargy 296.98 35.25 184 25004 17057 4596747
Metabolic disorder 295.46 35.25 89 25099 1327 4612477
Foetal exposure during pregnancy 293.51 35.25 204 24984 22965 4590839
Arrhythmia 274.89 35.25 161 25027 13471 4600333
Mental impairment 273.47 35.25 115 25073 4683 4609121
Pituitary tumour benign 271.92 35.25 69 25119 517 4613287
Fatigue 271.77 35.25 461 24727 145105 4468699
Orthostatic hypotension 267.23 35.25 126 25062 6748 4607056
Apathy 259.78 35.25 96 25092 2759 4611045
Syncope 255.75 35.25 218 24970 33177 4580627
Sinus bradycardia 253.77 35.25 106 25082 4243 4609561
Mutism 253.45 35.25 64 25124 469 4613335
Deep vein thrombosis 251.51 35.25 193 24995 25301 4588503
Aphasia 250.86 35.25 131 25057 8749 4605055
Emotional distress 248.35 35.25 117 25071 6253 4607551
Dizziness 248.31 35.25 361 24827 99510 4514294
Myoclonus 247.86 35.25 110 25078 5114 4608690
Thrombocytopenia 246.56 35.25 250 24938 47423 4566381
Hypertonia 246.50 35.25 92 25096 2720 4611084
Drooling 245.94 35.25 80 25108 1553 4612251
Polydipsia 242.55 35.25 77 25111 1378 4612426
Vomiting 241.88 35.25 393 24795 119306 4494498
Hepatocellular injury 241.79 35.25 123 25065 7777 4606027
Withdrawal syndrome 241.46 35.25 115 25073 6299 4607505
Psychomotor retardation 241.24 35.25 72 25116 1038 4612766
Anosognosia 240.32 35.25 49 25139 109 4613695
Weight decreased 237.88 35.25 261 24927 54203 4559601
Oromandibular dystonia 236.02 35.25 52 25136 190 4613614
Psychiatric symptom 236.01 35.25 80 25108 1773 4612031
Mental disorder 235.54 35.25 119 25069 7415 4606389
Intentional product misuse 234.57 35.25 163 25025 18330 4595474
Epilepsy 233.98 35.25 128 25060 9390 4604414
Hepatitis 232.59 35.25 139 25049 12066 4601738
Hypertension 229.79 35.25 248 24940 50550 4563254
Blood glucose increased 229.51 35.25 179 25009 24025 4589779
Hallucination, visual 228.84 35.25 108 25080 5794 4608010
Movement disorder 224.71 35.25 100 25088 4679 4609125
Hypokalaemia 223.18 35.25 159 25029 18601 4595203
Conduction disorder 214.04 35.25 61 25127 740 4613064
Stupor 210.23 35.25 69 25119 1379 4612425
Bradykinesia 209.21 35.25 66 25122 1156 4612648
Inappropriate schedule of product administration 208.97 35.25 164 25024 22206 4591598
Liver function test abnormal 208.91 35.25 139 25049 14553 4599251
Respiratory arrest 207.98 35.25 134 25054 13286 4600518
Tic 207.35 35.25 67 25121 1272 4612532
Torticollis 204.39 35.25 58 25130 692 4613112
Unresponsive to stimuli 202.90 35.25 119 25069 9974 4603830
Pneumonia 202.71 35.25 334 24854 102481 4511323
Ataxia 201.14 35.25 96 25092 5281 4608523
Persecutory delusion 200.85 35.25 61 25127 936 4612868
Mastitis 200.21 35.25 54 25134 526 4613278
Generalised tonic-clonic seizure 200.09 35.25 118 25070 9992 4603812
Antipsychotic drug level below therapeutic 199.16 35.25 47 25141 249 4613555
Floppy iris syndrome 196.49 35.25 43 25145 151 4613653
Affective disorder 194.92 35.25 68 25120 1647 4612157
Dyslipidaemia 191.62 35.25 67 25121 1634 4612170
Thinking abnormal 191.09 35.25 81 25107 3363 4610441
Wrong product administered 190.25 35.25 80 25108 3255 4610549
Dehydration 188.62 35.25 205 24983 42085 4571719
Hypokinesia 188.34 35.25 78 25110 3053 4610751
Torsade de pointes 186.59 35.25 83 25105 3878 4609926
Dementia 186.03 35.25 90 25098 5102 4608702
Anticholinergic syndrome 184.11 35.25 50 25138 501 4613303
Schizoaffective disorder 183.96 35.25 49 25139 453 4613351
Mental status changes 178.14 35.25 118 25070 12258 4601546
Personality change 177.98 35.25 68 25120 2146 4611658
Poisoning 176.95 35.25 91 25097 5883 4607921
Malaise 175.09 35.25 291 24897 89866 4523938
Product substitution issue 174.60 35.25 105 25083 9213 4604591
Psychomotor skills impaired 174.34 35.25 53 25135 816 4612988
Hypoglycaemia 174.16 35.25 136 25052 18273 4595531
Type 1 diabetes mellitus 172.81 35.25 61 25127 1531 4612273
Autonomic nervous system imbalance 170.91 35.25 53 25135 875 4612929
Refusal of treatment by patient 169.04 35.25 69 25119 2601 4611203
Posture abnormal 168.39 35.25 52 25136 846 4612958
Abnormal weight gain 167.52 35.25 46 25142 482 4613322
Accidental overdose 167.52 35.25 102 25086 9153 4604651
Reduced facial expression 167.51 35.25 43 25145 339 4613465
Embolism venous 167.37 35.25 53 25135 940 4612864
Choking 167.10 35.25 69 25119 2680 4611124
Ileus paralytic 167.02 35.25 63 25125 1918 4611886
Gestational diabetes 163.77 35.25 58 25130 1470 4612334
Hyperammonaemic encephalopathy 161.93 35.25 49 25139 742 4613062
Incontinence 160.45 35.25 66 25122 2538 4611266
Major depression 159.83 35.25 60 25128 1802 4612002
Urinary tract infection 155.95 35.25 186 25002 42204 4571600
Rabbit syndrome 153.93 35.25 31 25157 63 4613741
Respiratory depression 151.81 35.25 78 25110 5032 4608772
Erectile dysfunction 151.01 35.25 76 25112 4693 4609111
Blood triglycerides increased 148.77 35.25 78 25110 5247 4608557
Pancytopenia 148.22 35.25 141 25047 24712 4589092
Drug withdrawal syndrome 147.44 35.25 106 25082 12566 4601238
Electroencephalogram abnormal 146.91 35.25 54 25134 1527 4612277
Hyperglycaemia 146.34 35.25 101 25087 11221 4602583
Therapeutic response decreased 143.74 35.25 110 25078 14341 4599463
C-reactive protein increased 141.85 35.25 104 25084 12708 4601096
Body mass index increased 141.83 35.25 37 25151 313 4613491
Blood cholesterol increased 139.99 35.25 89 25099 8617 4605187
Agranulocytosis 139.00 35.25 84 25104 7433 4606371
Leukocytosis 137.80 35.25 84 25104 7550 4606254
Water intoxication 137.59 35.25 35 25153 265 4613539
Opisthotonus 136.90 35.25 35 25153 271 4613533
Enuresis 135.34 35.25 44 25144 852 4612952
White blood cell count decreased 134.82 35.25 153 25035 32912 4580892
Drug withdrawal syndrome neonatal 134.36 35.25 52 25136 1700 4612104
Ventricular extrasystoles 134.31 35.25 67 25121 4059 4609745
Mydriasis 133.70 35.25 65 25123 3723 4610081
Cerebral atrophy 133.69 35.25 51 25137 1602 4612202
Memory impairment 133.69 35.25 122 25066 20281 4593523
Adverse drug reaction 133.17 35.25 106 25082 14633 4599171
Alanine aminotransferase increased 132.52 35.25 141 25047 28232 4585572
Depressed mood 131.33 35.25 86 25102 8758 4605046
Euphoric mood 130.99 35.25 53 25135 1952 4611852
Therapeutic product effect incomplete 130.93 35.25 112 25076 17096 4596708
Disinhibition 130.78 35.25 40 25148 629 4613175
White blood cell count increased 129.89 35.25 106 25082 15161 4598643
Heart rate increased 129.63 35.25 115 25073 18427 4595377
Tachypnoea 128.89 35.25 69 25119 4842 4608962
Headache 128.18 35.25 305 24883 122068 4491736
Communication disorder 127.31 35.25 42 25146 853 4612951
Myocarditis 127.19 35.25 61 25127 3390 4610414
Eye movement disorder 126.84 35.25 53 25135 2121 4611683
Dry mouth 126.52 35.25 98 25090 13003 4600801
Asthenia 126.10 35.25 246 24942 85917 4527887
Sleep disorder 123.72 35.25 91 25097 11172 4602632
Drug level increased 123.39 35.25 73 25115 6213 4607591
Muscle twitching 123.05 35.25 67 25121 4864 4608940
Inappropriate affect 122.76 35.25 35 25153 425 4613379
Treatment failure 121.99 35.25 99 25089 14048 4599756
Aspartate aminotransferase increased 120.13 35.25 126 25062 24812 4588992
Eating disorder 119.88 35.25 60 25128 3660 4610144
Blood pressure decreased 119.16 35.25 108 25080 17792 4596012
Hepatic steatosis 118.79 35.25 71 25117 6157 4607647
Product dispensing error 118.21 35.25 70 25118 5967 4607837
Bradyphrenia 116.74 35.25 48 25140 1843 4611961
Impaired self-care 116.52 35.25 35 25153 516 4613288
Diet refusal 116.24 35.25 31 25157 288 4613516
Hepatic function abnormal 116.06 35.25 97 25091 14339 4599465
Diabetic ketoacidosis 115.53 35.25 75 25113 7525 4606279
Hypotonia 115.13 35.25 58 25130 3588 4610216
Poisoning deliberate 114.94 35.25 50 25138 2212 4611592
Depressive symptom 114.83 35.25 40 25148 964 4612840
Emotional disorder 114.64 35.25 57 25131 3428 4610376
Renal failure 113.52 35.25 157 25031 41212 4572592
Decreased appetite 113.31 35.25 185 25003 56212 4557592
Polydipsia psychogenic 111.32 35.25 24 25164 77 4613727
Electrocardiogram abnormal 111.11 35.25 52 25136 2734 4611070
Transaminases increased 108.65 35.25 79 25109 9527 4604277
Substance abuse 108.14 35.25 44 25144 1644 4612160
Libido decreased 107.59 35.25 46 25142 1950 4611854
Prolactin-producing pituitary tumour 107.00 35.25 24 25164 97 4613707
Intestinal obstruction 106.97 35.25 75 25113 8542 4605262
Menstrual disorder 106.30 35.25 38 25150 990 4612814
Cardiac failure 105.71 35.25 123 25065 27165 4586639
Drug ineffective for unapproved indication 105.03 35.25 64 25124 5747 4608057
Respiratory distress 104.83 35.25 82 25106 11034 4602770
Oropharyngeal spasm 104.57 35.25 24 25164 110 4613694
Feeling abnormal 104.16 35.25 141 25047 36264 4577540
Faecaloma 103.75 35.25 43 25145 1685 4612119
Alcohol abuse 103.65 35.25 37 25151 960 4612844
Acute psychosis 103.55 35.25 38 25150 1069 4612735
Brain oedema 102.51 35.25 59 25129 4768 4609036
Status epilepticus 100.99 35.25 59 25129 4904 4608900
Metabolic acidosis 100.85 35.25 84 25104 12356 4601448
Vision blurred 99.77 35.25 114 25074 24689 4589115
Encephalopathy 99.25 35.25 76 25112 9911 4603893
Logorrhoea 98.80 35.25 36 25152 992 4612812
Blood sodium decreased 98.27 35.25 61 25127 5661 4608143
Brain injury 98.03 35.25 44 25144 2099 4611705
Dyspnoea 97.66 35.25 299 24889 138686 4475118
Blunted affect 97.00 35.25 24 25164 160 4613644
Intracranial pressure increased 96.89 35.25 42 25146 1842 4611962
Bundle branch block right 96.60 35.25 44 25144 2173 4611631
Bipolar disorder 96.42 35.25 44 25144 2182 4611622
Negativism 95.41 35.25 26 25162 264 4613540
Parkinsonian gait 95.01 35.25 24 25164 176 4613628
Incoherent 94.78 35.25 41 25147 1789 4612015
Pemphigoid 94.40 35.25 44 25144 2292 4611512
Protrusion tongue 93.18 35.25 24 25164 192 4613612
Cystoid macular oedema 91.85 35.25 31 25157 677 4613127
Illusion 90.86 35.25 28 25160 452 4613352
Balance disorder 90.80 35.25 89 25099 16167 4597637
Hypernatraemia 89.83 35.25 41 25147 2034 4611770
Akinesia 89.55 35.25 30 25158 640 4613164
Aspiration 89.48 35.25 49 25139 3596 4610208
Drug-induced liver injury 88.95 35.25 67 25121 8524 4605280
Bladder dilatation 88.66 35.25 26 25162 351 4613453
Myocardial infarction 88.56 35.25 154 25034 49222 4564582
Attention deficit/hyperactivity disorder 88.08 35.25 33 25155 985 4612819
Palpitations 87.99 35.25 107 25081 24739 4589065
Sinus arrhythmia 86.81 35.25 28 25160 528 4613276
Hypercholesterolaemia 86.77 35.25 45 25143 2958 4610846
Breast enlargement 86.66 35.25 28 25160 531 4613273
Homicidal ideation 86.55 35.25 34 25154 1157 4612647
Compartment syndrome 86.42 35.25 33 25155 1039 4612765
Parkinson's disease 86.15 35.25 46 25142 3210 4610594
Staring 85.73 35.25 30 25158 733 4613071
Illness anxiety disorder 85.38 35.25 20 25168 102 4613702
Accidental exposure to product 83.91 35.25 79 25109 13653 4600151
Disease recurrence 83.70 35.25 61 25127 7380 4606424
Loss of personal independence in daily activities 83.45 35.25 63 25125 8042 4605762
Hyperreflexia 83.15 35.25 36 25152 1574 4612230
Motor dysfunction 82.87 35.25 41 25147 2439 4611365
Facial paralysis 82.68 35.25 51 25137 4679 4609125
Drug intolerance 82.51 35.25 97 25091 21649 4592155
Therapeutic product effect variable 81.77 35.25 24 25164 325 4613479
Emotional poverty 81.64 35.25 21 25167 167 4613637
Renal impairment 81.53 35.25 104 25084 25234 4588570
Drug resistance 81.03 35.25 62 25126 8074 4605730
Posturing 80.91 35.25 23 25165 276 4613528
Prescribed overdose 80.55 35.25 47 25141 3897 4609907
Dysphemia 80.53 35.25 30 25158 881 4612923
Gaze palsy 80.02 35.25 28 25160 684 4613120
Choreoathetosis 80.01 35.25 24 25164 352 4613452
Flat affect 79.37 35.25 26 25162 516 4613288
Supraventricular extrasystoles 79.24 35.25 34 25154 1454 4612350
Autism spectrum disorder 78.78 35.25 28 25160 717 4613087
Shock 78.13 35.25 63 25125 8853 4604951
Psychiatric decompensation 78.12 35.25 26 25162 543 4613261
Waxy flexibility 77.64 35.25 18 25170 87 4613717
Coma scale abnormal 77.36 35.25 34 25154 1542 4612262
Somatic symptom disorder of pregnancy 77.17 35.25 15 25173 23 4613781
Product prescribing error 76.53 35.25 57 25131 7129 4606675
Tongue disorder 76.46 35.25 35 25153 1748 4612056
Visual impairment 75.82 35.25 88 25100 19372 4594432
Product administration error 75.71 35.25 60 25128 8224 4605580
Cerebrovascular accident 75.30 35.25 131 25057 41869 4571935
Idiopathic intracranial hypertension 75.11 35.25 28 25160 824 4612980
Hypophagia 74.88 35.25 58 25130 7690 4606114
Hypersomnia 73.97 35.25 46 25142 4281 4609523
Hypertriglyceridaemia 73.02 35.25 37 25151 2316 4611488
Body temperature increased 72.77 35.25 52 25136 6100 4607704
Anger 72.21 35.25 50 25138 5579 4608225
Atrioventricular block first degree 71.89 35.25 35 25153 2010 4611794
Impulsive behaviour 71.61 35.25 28 25160 941 4612863
Wrong patient received product 70.86 35.25 24 25164 530 4613274
Mood swings 70.28 35.25 49 25139 5528 4608276
Precocious puberty 69.99 35.25 18 25170 143 4613661
Hypothyroidism 69.76 35.25 56 25132 7818 4605986
Hyperphagia 69.58 35.25 24 25164 561 4613243
Maternal exposure during pregnancy 69.46 35.25 79 25109 17014 4596790
Drug dependence 69.18 35.25 53 25135 6914 4606890
Respiratory dyskinesia 68.53 35.25 13 25175 16 4613788
Psychotic behaviour 68.49 35.25 21 25167 333 4613471
Head injury 68.40 35.25 54 25134 7361 4606443
Hyperammonaemia 67.60 35.25 34 25154 2095 4611709
Breast tenderness 67.49 35.25 26 25162 839 4612965
Obsessive thoughts 67.32 35.25 22 25166 433 4613371
Bipolar I disorder 67.03 35.25 24 25164 628 4613176
Decreased activity 66.86 35.25 31 25157 1595 4612209
Spasmodic dysphonia 66.41 35.25 15 25173 63 4613741
Electrocardiogram T wave abnormal 66.19 35.25 24 25164 652 4613152
Circulatory collapse 66.08 35.25 54 25134 7731 4606073
Fear 65.62 35.25 42 25146 4110 4609694
Gait inability 65.54 35.25 59 25129 9626 4604178
Cyanosis 65.47 35.25 49 25139 6173 4607631
Hyponatraemic seizure 65.28 35.25 16 25172 102 4613702
Pancreatitis acute 65.20 35.25 56 25132 8587 4605217
Oedema peripheral 65.17 35.25 123 25065 41849 4571955
Trismus 65.04 35.25 30 25158 1525 4612279
Colitis ischaemic 65.02 35.25 36 25152 2699 4611105
Somatic symptom disorder 64.99 35.25 22 25166 485 4613319
Insurance issue 64.97 35.25 24 25164 688 4613116
Language disorder 64.93 35.25 23 25165 583 4613221
Drug abuser 64.88 35.25 36 25152 2711 4611093
Hypomania 64.49 35.25 30 25158 1555 4612249
Stereotypy 64.29 35.25 19 25169 264 4613540
Acute generalised exanthematous pustulosis 64.24 35.25 37 25151 2993 4610811
Blood sodium increased 63.80 35.25 26 25162 975 4612829
Therapy non-responder 63.50 35.25 73 25115 15904 4597900
Hallucinations, mixed 63.42 35.25 27 25161 1132 4612672
Self-injurious ideation 63.41 35.25 26 25162 991 4612813
Abulia 63.32 35.25 18 25170 216 4613588
Anal incontinence 63.11 35.25 37 25151 3094 4610710
Clonus 63.00 35.25 27 25161 1151 4612653
Breast discharge 62.87 35.25 20 25168 360 4613444
Haemodynamic instability 62.25 35.25 35 25153 2704 4611100
Screaming 62.20 35.25 27 25161 1188 4612616
Abdominal pain 62.02 35.25 149 25039 59875 4553929
Wellens' syndrome 60.73 35.25 10 25178 0 4613804
Vertigo 60.56 35.25 69 25119 14887 4598917
Blood alkaline phosphatase increased 59.85 35.25 63 25125 12444 4601360
Gamma-glutamyltransferase increased 59.85 35.25 60 25128 11194 4602610
Compulsions 59.48 35.25 16 25172 154 4613650
Antipsychotic drug level increased 59.01 35.25 27 25161 1347 4612457
Pallor 58.92 35.25 50 25138 7542 4606262
Respiratory failure 58.85 35.25 98 25090 30228 4583576
Resting tremor 58.84 35.25 17 25171 217 4613587
Therapeutic product effect decreased 58.79 35.25 76 25112 18677 4595127
Swollen tongue 58.61 35.25 53 25135 8697 4605107
Sepsis 58.57 35.25 119 25069 42720 4571084
Visceral congestion 58.40 35.25 16 25172 166 4613638
Restless legs syndrome 58.24 35.25 37 25151 3574 4610230
Amnesia 58.15 35.25 63 25125 12858 4600946
Hepatic enzyme increased 58.11 35.25 74 25114 17917 4595887
Selective eating disorder 57.77 35.25 24 25164 946 4612858
Nervous system disorder 57.53 35.25 46 25142 6385 4607419
Maternal drugs affecting foetus 57.50 35.25 38 25150 3927 4609877
Asphyxia 57.42 35.25 31 25157 2211 4611593
Cholestasis 57.08 35.25 50 25138 7870 4605934
Behaviour disorder 56.95 35.25 18 25170 317 4613487
Diabetes insipidus 56.60 35.25 23 25165 856 4612948
Bundle branch block left 56.36 35.25 29 25159 1875 4611929
Immobile 56.24 35.25 24 25164 1012 4612792
Multiple drug therapy 56.24 35.25 14 25174 96 4613708
Nausea 55.09 35.25 296 24892 177037 4436767
Paroxysmal perceptual alteration 54.85 35.25 10 25178 8 4613796
Ventricular tachycardia 54.10 35.25 47 25141 7317 4606487
Subileus 53.88 35.25 24 25164 1124 4612680
Cardiogenic shock 53.45 35.25 41 25147 5357 4608447
Hyperkinesia 53.40 35.25 19 25169 488 4613316
Affect lability 53.39 35.25 35 25153 3567 4610237
Dysstasia 52.85 35.25 39 25149 4808 4608996
Substance-induced psychotic disorder 52.73 35.25 20 25168 618 4613186
Drug reaction with eosinophilia and systemic symptoms 52.52 35.25 57 25131 11656 4602148
Lactation disorder 52.40 35.25 14 25174 131 4613673
Dysuria 52.13 35.25 48 25140 8062 4605742
Venous thrombosis 52.02 35.25 27 25161 1777 4612027
Malignant catatonia 51.58 35.25 11 25177 33 4613771
Cerebral ischaemia 51.55 35.25 30 25158 2474 4611330
Poor quality sleep 50.71 35.25 33 25155 3322 4610482
Suicidal behaviour 50.40 35.25 22 25166 981 4612823
Menstruation irregular 50.40 35.25 26 25162 1690 4612114
Joint dislocation 50.24 35.25 28 25160 2126 4611678
Physical assault 50.15 35.25 19 25169 585 4613219
Wolff-Parkinson-White syndrome 49.64 35.25 14 25174 163 4613641
Bedridden 49.60 35.25 28 25160 2180 4611624
Jaundice 49.57 35.25 57 25131 12417 4601387
Red blood cell count decreased 49.25 35.25 47 25141 8256 4605548
Ejaculation disorder 49.19 35.25 18 25170 502 4613302
Diplopia 49.06 35.25 42 25146 6409 4607395
Dysphoria 49.04 35.25 30 25158 2711 4611093
Platelet count decreased 48.75 35.25 98 25090 34904 4578900
Antipsychotic drug level above therapeutic 48.59 35.25 17 25171 415 4613389
Tension 48.37 35.25 21 25167 924 4612880
Paradoxical drug reaction 48.36 35.25 22 25166 1083 4612721
Personality disorder 48.21 35.25 19 25169 652 4613152
Bradyarrhythmia 48.03 35.25 20 25168 793 4613011
Talipes 47.85 35.25 22 25166 1110 4612694
Hyporesponsive to stimuli 47.55 35.25 16 25172 346 4613458
Rapid eye movement sleep behaviour disorder 47.30 35.25 11 25177 54 4613750
Respiration abnormal 47.01 35.25 22 25166 1156 4612648
Atrial tachycardia 46.97 35.25 19 25169 699 4613105
Blindness 46.86 35.25 43 25145 7189 4606615
Keratoconus 46.81 35.25 11 25177 57 4613747
Diabetic neuropathy 46.71 35.25 21 25167 1005 4612799
Neuroleptic-induced deficit syndrome 46.03 35.25 8 25180 3 4613801
Hypotonia neonatal 45.97 35.25 18 25170 607 4613197
Blood creatinine increased 45.73 35.25 82 25106 26818 4586986
Supraventricular tachycardia 45.71 35.25 33 25155 3932 4609872
Acidosis 45.45 35.25 31 25157 3375 4610429
Anuria 45.34 35.25 33 25155 3982 4609822
Premature baby 45.21 35.25 49 25139 10002 4603802
Cortisol increased 45.21 35.25 13 25175 163 4613641
Myoglobin blood increased 45.19 35.25 19 25169 772 4613032
Hiccups 45.06 35.25 25 25163 1882 4611922
Optic atrophy 44.76 35.25 18 25170 652 4613152
Delusional disorder, unspecified type 44.75 35.25 14 25174 238 4613566
Myopathy toxic 44.59 35.25 14 25174 241 4613563
Energy increased 44.57 35.25 19 25169 799 4613005
Electrolyte imbalance 44.45 35.25 32 25156 3797 4610007
Neurotoxicity 44.44 35.25 37 25151 5436 4608368
Hypersexuality 44.32 35.25 17 25171 542 4613262
Self esteem decreased 44.29 35.25 15 25173 331 4613473
Breast pain 44.15 35.25 24 25164 1735 4612069
Liver disorder 44.08 35.25 55 25133 13043 4600761
Dementia with Lewy bodies 44.03 35.25 13 25175 180 4613624
Ileus 44.01 35.25 36 25152 5160 4608644
Electrocardiogram T wave inversion 43.79 35.25 21 25167 1166 4612638
Coordination abnormal 43.26 35.25 31 25157 3651 4610153
Tourette's disorder 43.13 35.25 13 25175 194 4613610
Gambling disorder 43.03 35.25 18 25170 722 4613082
Anaemia 42.91 35.25 146 25042 71414 4542390
Cardiovascular disorder 42.90 35.25 37 25151 5703 4608101
Accidental exposure to product by child 42.74 35.25 23 25165 1630 4612174
Suspiciousness 42.70 35.25 13 25175 201 4613603
Sedation complication 42.69 35.25 15 25173 371 4613433
Therapeutic response unexpected 42.62 35.25 40 25148 6882 4606922
Electrocardiogram ST-T change 42.57 35.25 15 25173 374 4613430
Labelled drug-drug interaction medication error 42.50 35.25 29 25159 3159 4610645
Hepatitis cholestatic 42.47 35.25 27 25161 2611 4611193
Blood bilirubin increased 42.38 35.25 53 25135 12599 4601205
Product administered to patient of inappropriate age 42.35 35.25 25 25163 2117 4611687
Cerebral infarction 42.21 35.25 49 25139 10783 4603021
Derealisation 41.95 35.25 15 25173 391 4613413
Feeling guilty 41.89 35.25 13 25175 215 4613589
Neutrophil count increased 41.88 35.25 34 25154 4821 4608983
Frontotemporal dementia 41.69 35.25 12 25176 151 4613653
Pulmonary oedema 41.24 35.25 57 25131 14929 4598875
Feeding disorder 41.19 35.25 26 25162 2483 4611321
Cardiac disorder 41.10 35.25 61 25127 17048 4596756
Tonic convulsion 40.99 35.25 16 25172 535 4613269
Small for dates baby 40.98 35.25 24 25164 2003 4611801
CSF pressure increased 40.97 35.25 11 25177 105 4613699
Pituitary tumour 40.88 35.25 14 25174 320 4613484
Locked-in syndrome 40.78 35.25 12 25176 164 4613640
Oligomenorrhoea 40.71 35.25 13 25175 237 4613567
Oesophageal atresia 40.63 35.25 14 25174 326 4613478
Hyperglycaemic hyperosmolar nonketotic syndrome 40.47 35.25 14 25174 330 4613474
Stevens-Johnson syndrome 40.41 35.25 43 25145 8596 4605208
Breast cancer 40.41 35.25 47 25141 10364 4603440
Product quality issue 40.39 35.25 66 25122 20033 4593771
Excessive eye blinking 40.26 35.25 13 25175 246 4613558
Chorea 40.19 35.25 16 25172 564 4613240
Infertility 40.00 35.25 14 25174 342 4613462
Compulsive sexual behaviour 39.87 35.25 10 25178 71 4613733
Hemivertebra 39.87 35.25 10 25178 71 4613733
Sexually inappropriate behaviour 39.82 35.25 11 25177 118 4613686
Gastrointestinal disorder 39.65 35.25 58 25130 16003 4597801
Product dose omission 39.60 35.25 136 25052 66826 4546978
Symptom masked 39.39 35.25 12 25176 186 4613618
Respiratory disorder neonatal 39.39 35.25 16 25172 595 4613209
Caput succedaneum 39.35 35.25 7 25181 4 4613800
Grimacing 39.27 35.25 12 25176 188 4613616
Foetal alcohol syndrome 39.25 35.25 9 25179 41 4613763
Thrombophlebitis 39.25 35.25 21 25167 1471 4612333
Abortion spontaneous 39.09 35.25 54 25134 14138 4599666
Congenital anomaly 39.00 35.25 24 25164 2192 4611612
Muscle contracture 38.84 35.25 16 25172 617 4613187
Drug hypersensitivity 38.79 35.25 137 25051 68263 4545541
Breast swelling 38.76 35.25 14 25174 376 4613428
Inadequate diet 38.54 35.25 11 25177 134 4613670
Decubitus ulcer 38.48 35.25 25 25163 2509 4611295
Facial spasm 38.47 35.25 13 25175 285 4613519
Bruxism 38.13 35.25 19 25169 1147 4612657
Hypometabolism 38.08 35.25 9 25179 48 4613756
Nightmare 38.06 35.25 38 25150 7052 4606752
Slow response to stimuli 37.97 35.25 14 25174 399 4613405
Premature labour 37.87 35.25 24 25164 2308 4611496
Atrioventricular block 37.84 35.25 26 25162 2864 4610940
Fluid intake reduced 37.81 35.25 19 25169 1168 4612636
Breast mass 37.79 35.25 20 25168 1370 4612434
Ventricular septal defect 37.47 35.25 24 25164 2351 4611453
Mastication disorder 37.46 35.25 16 25172 676 4613128
Drug level decreased 37.43 35.25 24 25164 2355 4611449
Hyperthermia malignant 37.42 35.25 16 25172 678 4613126
Atrioventricular block second degree 37.40 35.25 20 25168 1399 4612405
Polyuria 37.21 35.25 25 25163 2655 4611149
Nystagmus 37.17 35.25 24 25164 2384 4611420
Arachnoid cyst 37.14 35.25 11 25177 154 4613650
Granuloma 37.01 35.25 19 25169 1222 4612582
Polycystic ovaries 36.82 35.25 12 25176 234 4613570
Diabetic coma 36.77 35.25 14 25174 437 4613367
Retinal vein occlusion 36.40 35.25 18 25170 1069 4612735
Hostility 36.37 35.25 15 25173 580 4613224
Toxic skin eruption 36.37 35.25 30 25158 4350 4609454
Imprisonment 36.26 35.25 12 25176 246 4613558
Eosinophil count decreased 36.24 35.25 14 25174 455 4613349
Potentiating drug interaction 36.10 35.25 20 25168 1501 4612303
Glucose tolerance impaired 36.09 35.25 18 25170 1089 4612715
Atrioventricular block complete 36.06 35.25 26 25162 3092 4610712
Neglect of personal appearance 35.99 35.25 9 25179 63 4613741
Neutrophil count decreased 35.98 35.25 51 25137 13672 4600132
Alcohol poisoning 35.92 35.25 17 25171 916 4612888
Autoimmune thyroiditis 35.89 35.25 17 25171 918 4612886
Frustration tolerance decreased 35.71 35.25 19 25169 1316 4612488
Sleep apnoea syndrome 35.60 35.25 30 25158 4481 4609323
Meige's syndrome 35.53 35.25 8 25180 33 4613771
Alcoholism 35.51 35.25 17 25171 940 4612864
Painful erection 35.41 35.25 10 25178 117 4613687
Malnutrition 35.26 35.25 27 25161 3518 4610286

Pharmacologic Action:

SourceCodeDescription
ATC N05AX08 NERVOUS SYSTEM
PSYCHOLEPTICS
ANTIPSYCHOTICS
Other antipsychotics
MeSH PA D014150 Antipsychotic Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D015259 Dopamine Agents
MeSH PA D018492 Dopamine Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D011619 Psychotropic Drugs
MeSH PA D018490 Serotonin Agents
MeSH PA D012702 Serotonin Antagonists
CHEBI has role CHEBI:48561 dopaminergic antagonist
CHEBI has role CHEBI:35471 psychotropic drug
CHEBI has role CHEBI:65191 second generation antipsychotic
CHEBI has role CHEBI:48279 serotonergic antagonist
CHEBI has role CHEBI:37890 alpha-adrenergic antagonist
CHEBI has role CHEBI:37955 H1-receptor antagonist
FDA EPC N0000175430 Atypical Antipsychotic
MeSH PA D014149 Tranquilizing Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Mixed bipolar I disorder indication 16506000 DOID:3312
Schizophrenia indication 58214004 DOID:5419
Bipolar disorder in remission indication 85248005
Bipolar affective disorder, current episode manic indication 191618007
Infantile autism indication 408857007
Bipolar affective disorder, current episode depression off-label use 191627008 DOID:3312
Toxoplasmosis associated with acquired immunodeficiency syndrome off-label use 421666009
Depression Treatment Adjunct off-label use
Priapism contraindication 6273006 DOID:9286
Suicidal thoughts contraindication 6471006
Asthenia contraindication 13791008
Neuroleptic malignant syndrome contraindication 15244003 DOID:14464
Senile dementia contraindication 15662003
Agranulocytosis contraindication 17182001 DOID:12987
Myocardial infarction contraindication 22298006 DOID:5844
Hypovolemia contraindication 28560003
Orthostatic hypotension contraindication 28651003
Parkinsonism contraindication 32798002
Dehydration contraindication 34095006
Dysphagia contraindication 40739000
Conduction disorder of the heart contraindication 44808001
Low blood pressure contraindication 45007003
Chronic heart failure contraindication 48447003
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Hyperlipidemia contraindication 55822004 DOID:1168
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Cerebrovascular disease contraindication 62914000 DOID:6713
Substance abuse contraindication 66214007
Diabetes mellitus contraindication 73211009 DOID:9351
Diffuse Lewy body disease contraindication 80098002
Hyperglycemia contraindication 80394007 DOID:4195
Leukopenia contraindication 84828003 DOID:615
Tardive dyskinesia contraindication 102449007
Seizure disorder contraindication 128613002
Cerebrovascular accident contraindication 230690007
Disease of liver contraindication 235856003 DOID:409
Metabolic syndrome X contraindication 237602007 DOID:14221
Hyperprolactinemia contraindication 237662005 DOID:12700
Retention of urine contraindication 267064002
Neutropenic disorder contraindication 303011007 DOID:1227
At risk for aspiration contraindication 371736008
Fever contraindication 386661006
Hypothermia contraindication 386689009
Impaired cognition contraindication 386806002
Breastfeeding (mother) contraindication 413712001
Myocardial ischemia contraindication 414795007 DOID:3393
Obesity contraindication 414916001 DOID:9970
Carcinoma of female breast contraindication 447782002
Smokes tobacco daily contraindication 449868002
Predisposed to Torsades de Pointes Cardiac Arrhythmias contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.78 Basic
pKa2 3.45 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
120MG PERSERIS KIT INDIVIOR INC N210655 July 27, 2018 RX FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 10406160 June 26, 2026 METHOD OF TREATING SCHIZOPHRENIA
90MG PERSERIS KIT INDIVIOR INC N210655 July 27, 2018 RX FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 10406160 June 26, 2026 METHOD OF TREATING SCHIZOPHRENIA
120MG PERSERIS KIT INDIVIOR INC N210655 July 27, 2018 RX FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 10058554 Sept. 26, 2026 ADMINISTRATION OF RISPERIDONE
90MG PERSERIS KIT INDIVIOR INC N210655 July 27, 2018 RX FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 10058554 Sept. 26, 2026 ADMINISTRATION OF RISPERIDONE
120MG PERSERIS KIT INDIVIOR INC N210655 July 27, 2018 RX FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 10376590 Feb. 13, 2028 METHOD OF TREATING SCHIZOPHRENIA
120MG PERSERIS KIT INDIVIOR INC N210655 July 27, 2018 RX FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9186413 Feb. 13, 2028 TREATMENT OF SCHIZOPHRENIA
90MG PERSERIS KIT INDIVIOR INC N210655 July 27, 2018 RX FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 10376590 Feb. 13, 2028 METHOD OF TREATING SCHIZOPHRENIA
90MG PERSERIS KIT INDIVIOR INC N210655 July 27, 2018 RX FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9186413 Feb. 13, 2028 TREATMENT OF SCHIZOPHRENIA

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
120MG PERSERIS KIT INDIVIOR INC N210655 July 27, 2018 RX FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS July 27, 2021 NEW PRODUCT
90MG PERSERIS KIT INDIVIOR INC N210655 July 27, 2018 RX FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS July 27, 2021 NEW PRODUCT

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
D(2) dopamine receptor GPCR ANTAGONIST Ki 8.49 WOMBAT-PK CHEMBL
5-hydroxytryptamine receptor 2A GPCR ANTAGONIST Ki 9.36 WOMBAT-PK CHEMBL
D(3) dopamine receptor GPCR ANTAGONIST Ki 8.07 WOMBAT-PK
Histamine H2 receptor GPCR Ki 6.92 PDSP
D(1B) dopamine receptor GPCR Ki 7.02 PDSP
Muscarinic acetylcholine receptor M3 GPCR Ki 5 PDSP
Muscarinic acetylcholine receptor M4 GPCR Ki 5.54 PDSP
Muscarinic acetylcholine receptor M2 GPCR Ki 5.43 PDSP
Alpha-1D adrenergic receptor GPCR ANTAGONIST Ki 7.40 IUPHAR
5-hydroxytryptamine receptor 1F GPCR ANTAGONIST Ki 5.90 IUPHAR
5-hydroxytryptamine receptor 1E GPCR ANTAGONIST Ki 5.90 IUPHAR
Cytochrome P450 2D6 Enzyme IC50 5.28 DRUG MATRIX
5-hydroxytryptamine receptor 2C GPCR ANTAGONIST Ki 7.70 WOMBAT-PK
5-hydroxytryptamine receptor 5A GPCR Ki 6.69 WOMBAT-PK
Alpha-1B adrenergic receptor GPCR Ki 8.48 WOMBAT-PK
Alpha-2C adrenergic receptor GPCR Ki 8.49 WOMBAT-PK
5-hydroxytryptamine receptor 1D GPCR ANTAGONIST Ki 7.60 WOMBAT-PK
5-hydroxytryptamine receptor 1B GPCR ANTAGONIST Ki 7.49 WOMBAT-PK
Histamine H1 receptor GPCR Ki 7.48 WOMBAT-PK
Alpha-2B adrenergic receptor GPCR Ki 7.77 WOMBAT-PK
Alpha-1A adrenergic receptor GPCR Ki 8.55 WOMBAT-PK
5-hydroxytryptamine receptor 7 GPCR Ki 8.47 WOMBAT-PK
5-hydroxytryptamine receptor 2B GPCR Ki 7.42 WOMBAT-PK
5-hydroxytryptamine receptor 1A GPCR Ki 6.44 WOMBAT-PK
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 6.79 WOMBAT-PK
Alpha-2A adrenergic receptor GPCR Ki 8 WOMBAT-PK
Beta-2 adrenergic receptor GPCR Ki 5.30 PDSP
Beta-1 adrenergic receptor GPCR Ki 5.30 PDSP
Solute carrier family 22 member 2 Transporter IC50 4.96 CHEMBL
Muscarinic acetylcholine receptor M1 GPCR Ki 5.55 CHEMBL
D(1A) dopamine receptor GPCR Ki 7.68 CHEMBL
Sodium-dependent serotonin transporter Transporter Ki 5.85 CHEMBL
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 5.37 CHEMBL
Multidrug and toxin extrusion protein 1 Transporter IC50 5.80 CHEMBL
5-hydroxytryptamine receptor 6 GPCR Ki 6.65 CHEMBL
Glycine receptor subunit alpha-1 Ion channel EC50 6.49 CHEMBL
D(4) dopamine receptor GPCR ANTAGONIST Ki 8 WOMBAT-PK
Alpha-1B adrenergic receptor GPCR Ki 8.97 DRUG MATRIX
Transporter Transporter Ki 4.55 CHEMBL
Histamine H1 receptor GPCR Ki 7.66 CHEMBL
5-hydroxytryptamine receptor 7 GPCR Ki 8.85 CHEMBL
D(2) dopamine receptor GPCR IC50 7.64 CHEMBL
D(3) dopamine receptor GPCR Ki 8.01 CHEMBL
Serotonin 2 (5-HT2) receptor GPCR Ki 9.85 CHEMBL
D(1A) dopamine receptor GPCR Ki 7.66 CHEMBL
Alpha-2A adrenergic receptor GPCR Ki 7.60 CHEMBL
Histamine H1 receptor GPCR IC50 7.10 CHEMBL
5-hydroxytryptamine receptor 2C GPCR Ki 7.84 CHEMBL
5-hydroxytryptamine receptor 1A GPCR IC50 6.37 CHEMBL
5-hydroxytryptamine receptor 2A GPCR Ki 9.82 CHEMBL
Beta-1 adrenergic receptor GPCR Ki 4.66 CHEMBL
Alpha-1A adrenergic receptor GPCR Ki 7.89 CHEMBL
Serotonin 1 (5-HT1) receptor GPCR Ki 6.47 CHEMBL
5-hydroxytryptamine receptor 1A GPCR Ki 6.89 CHEMBL
Serotonin 2 (5-HT2) receptor GPCR IC50 8.82 CHEMBL
D(2) dopamine receptor GPCR Ki 8.74 CHEMBL
5-hydroxytryptamine receptor 6 GPCR ANTAGONIST Ki 6.40 IUPHAR

External reference:

IDSource
4020840 VUID
N0000148350 NUI
C0073393 UMLSCUI
D00426 KEGG_DRUG
108386000 SNOMEDCT_US
4020840 VANDF
004392 NDDF
35636 RXNORM
146973 MMSL
d03180 MMSL
386840002 SNOMEDCT_US
5429 MMSL
CHEMBL85 ChEMBL_ID
DB00734 DRUGBANK_ID
L6UH7ZF8HC UNII
6085 INN_ID
CHEBI:8871 CHEBI
D018967 MESH_DESCRIPTOR_UI
5073 PUBCHEM_CID
96 IUPHAR_LIGAND_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Risperidone HUMAN PRESCRIPTION DRUG LABEL 1 0054-0063 SOLUTION 1 mg ORAL ANDA 20 sections
Risperidone HUMAN PRESCRIPTION DRUG LABEL 1 0378-3502 TABLET, FILM COATED 0.25 mg ORAL ANDA 18 sections
Risperidone HUMAN PRESCRIPTION DRUG LABEL 1 0378-3505 TABLET, FILM COATED 0.50 mg ORAL ANDA 18 sections
Risperidone HUMAN PRESCRIPTION DRUG LABEL 1 0378-3511 TABLET, FILM COATED 1 mg ORAL ANDA 18 sections
Risperidone HUMAN PRESCRIPTION DRUG LABEL 1 0378-3512 TABLET, FILM COATED 2 mg ORAL ANDA 18 sections
Risperidone HUMAN PRESCRIPTION DRUG LABEL 1 0378-3513 TABLET, FILM COATED 3 mg ORAL ANDA 18 sections
Risperidone HUMAN PRESCRIPTION DRUG LABEL 1 0378-3514 TABLET, FILM COATED 4 mg ORAL ANDA 18 sections
Risperidone HUMAN PRESCRIPTION DRUG LABEL 1 0615-8196 TABLET 0.25 mg ORAL ANDA 19 sections
Risperidone HUMAN PRESCRIPTION DRUG LABEL 1 0615-8197 TABLET 0.50 mg ORAL ANDA 19 sections
Risperidone HUMAN PRESCRIPTION DRUG LABEL 1 0615-8198 TABLET 1 mg ORAL ANDA 19 sections
Risperidone HUMAN PRESCRIPTION DRUG LABEL 1 0615-8265 TABLET 3 mg ORAL ANDA 19 sections
Risperidone HUMAN PRESCRIPTION DRUG LABEL 1 0615-8288 TABLET 2 mg ORAL ANDA 19 sections
Risperidone HUMAN PRESCRIPTION DRUG LABEL 1 0781-5310 TABLET, ORALLY DISINTEGRATING 0.50 mg ORAL ANDA 18 sections
Risperidone HUMAN PRESCRIPTION DRUG LABEL 1 0781-5311 TABLET, ORALLY DISINTEGRATING 1 mg ORAL ANDA 18 sections
Risperidone HUMAN PRESCRIPTION DRUG LABEL 1 0781-5312 TABLET, ORALLY DISINTEGRATING 2 mg ORAL ANDA 18 sections
Risperidone HUMAN PRESCRIPTION DRUG LABEL 1 0781-5313 TABLET, ORALLY DISINTEGRATING 3 mg ORAL ANDA 18 sections
Risperidone HUMAN PRESCRIPTION DRUG LABEL 1 0781-5314 TABLET, ORALLY DISINTEGRATING 4 mg ORAL ANDA 18 sections
Risperidone HUMAN PRESCRIPTION DRUG LABEL 1 0904-6357 TABLET 0.25 mg ORAL ANDA 20 sections
Risperidone HUMAN PRESCRIPTION DRUG LABEL 1 0904-6358 TABLET 0.50 mg ORAL ANDA 20 sections
Risperidone HUMAN PRESCRIPTION DRUG LABEL 1 0904-6359 TABLET 1 mg ORAL ANDA 20 sections
Risperidone HUMAN PRESCRIPTION DRUG LABEL 1 0904-6360 TABLET 2 mg ORAL ANDA 20 sections
Risperidone HUMAN PRESCRIPTION DRUG LABEL 1 0904-6361 TABLET 3 mg ORAL ANDA 20 sections
Risperidone HUMAN PRESCRIPTION DRUG LABEL 1 0904-6362 TABLET 4 mg ORAL ANDA 20 sections
PERSERIS HUMAN PRESCRIPTION DRUG LABEL 1 12496-0090 KIT 90 mg SUBCUTANEOUS NDA 17 sections
PERSERIS HUMAN PRESCRIPTION DRUG LABEL 1 12496-0120 KIT 120 mg SUBCUTANEOUS NDA 17 sections
Risperidone HUMAN PRESCRIPTION DRUG LABEL 1 13107-119 TABLET, FILM COATED 0.25 mg ORAL ANDA 20 sections
Risperidone HUMAN PRESCRIPTION DRUG LABEL 1 13107-120 TABLET, FILM COATED 0.50 mg ORAL ANDA 20 sections
Risperidone HUMAN PRESCRIPTION DRUG LABEL 1 13107-121 TABLET, FILM COATED 1 mg ORAL ANDA 20 sections
Risperidone HUMAN PRESCRIPTION DRUG LABEL 1 13107-122 TABLET, FILM COATED 2 mg ORAL ANDA 20 sections
Risperidone HUMAN PRESCRIPTION DRUG LABEL 1 13107-123 TABLET, FILM COATED 3 mg ORAL ANDA 20 sections